Neurocrine Biosciences (NBIX) return on equity (ROE)

Return on equity · fiscal 2025
14.7%

Neurocrine Biosciences (NBIX) earned a return on equity of 14.7% in fiscal 2025 (the year ended December 31, 2025). That is 1.5 percentage points higher than the 13.2% of fiscal 2024. Figures as of 18 Nov 2026, 02:54 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
14.7%
Change on fiscal 2024
+1.5 pts
Highest on record
62.5%fiscal 2011
Lowest on record
-1290.8%fiscal 2009
Fiscal years on record
172009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Neurocrine Biosciences return on equity (ROE), in more detail

Across the 17 fiscal years on record (2009–2025), the highest was 62.5% in fiscal 2011 and the lowest -1290.8% in fiscal 2009. The fiscal 2025 figure is higher than in 88% of the 16 earlier fiscal years on record, whose median is 3.8%.

History · 17 fiscal years

Return on equity by fiscal year

Neurocrine Biosciences return on equity (ROE), year by year

Neurocrine Biosciences (NBIX) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202514.7% 1.5 pts up
202413.2% 2.0 pts up
202311.2% 2.1 pts up
20229.0% 2.5 pts up
20216.5% 29.6 pts down
202036.2% 30.4 pts up
20195.8% 1.4 pts up
20184.4% 42.7 pts up
2017-38.3% 6.5 pts up
2016-44.8% 23.9 pts down
2015-21.0% 8.1 pts up
2014-29.0% 9.3 pts up
2013-38.3% 41.5 pts down
20123.3% 59.3 pts down
201162.5% 103.7 pts up
2010-41.2% 1249.6 pts up
2009-1290.8%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Neurocrine Biosciences and comparable companies
CompanyReturn on equityFiscal year
Revvity RVTY3.3%2025
Exelixis EXEL36.2%2025
Charles River Laboratories International CRL-4.6%2025
Neurocrine Biosciences NBIX14.7%2025
Ascendis Pharma ASND-221.5%2022
ICON ICLR2.5%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on NBIX

Neurocrine Biosciences, figure by figure

Neurocrine Biosciences (NBIX) overview: price, valuation and scorecardAll health care companies by market value

Neurocrine Biosciences return on equity (ROE): questions and answers

What is Neurocrine Biosciences's return on equity?

Neurocrine Biosciences (NBIX) earned a return on equity of 14.7% in fiscal 2025 (the year ended December 31, 2025). That is 1.5 percentage points higher than the 13.2% of fiscal 2024.

Is Neurocrine Biosciences's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 88% of the 16 earlier fiscal years on record, whose median is 3.8%.

What are the highest and lowest return on equity figures on record for Neurocrine Biosciences?

Across the 17 fiscal years on record (2009–2025), the highest was 62.5% in fiscal 2011 and the lowest -1290.8% in fiscal 2009.

How is Neurocrine Biosciences's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Neurocrine Biosciences (NBIX) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/NBIX/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.